These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 9297348)

  • 21. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.
    Jones SM; Feldmann H; Ströher U; Geisbert JB; Fernando L; Grolla A; Klenk HD; Sullivan NJ; Volchkov VE; Fritz EA; Daddario KM; Hensley LE; Jahrling PB; Geisbert TW
    Nat Med; 2005 Jul; 11(7):786-90. PubMed ID: 15937495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Recent Advances in Vaccines and Drugs Against the Ebola Virus].
    Zhu X; Yao C; Wei Y; Kou Z; Hu K
    Bing Du Xue Bao; 2015 May; 31(3):287-92. PubMed ID: 26470536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine.
    Zhou Y; Sullivan NJ
    Curr Opin Immunol; 2015 Aug; 35():131-6. PubMed ID: 26247875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Towards a vaccine against Ebola virus.
    Geisbert TW; Jahrling PB
    Expert Rev Vaccines; 2003 Dec; 2(6):777-89. PubMed ID: 14711361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of inactivated Ebola virus on colony forming activity of human hematopoietic stem cells].
    Chepurnov AA; Tiunnikov GI; Chernukhin IV
    Vopr Virusol; 1997; 42(2):91-2. PubMed ID: 9182409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of inactivated vaccines prepared with parainfluenza viruses type 1 and type 3, administered experimentally by nasal or oral route.
    Petrescu AL; Petica M; Bârnaure F; Athanasiu P
    Rom J Virol; 1998; 49(1-4):97-115. PubMed ID: 10892431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Ebola virus reproduction in cell cultures].
    Titenko AM; Novozhilov SS; Andaev EI; Borisova TI; Kulikova EV
    Vopr Virusol; 1992; 37(2):110-3. PubMed ID: 1279896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Knockdown of Ebola virus VP24 impairs viral nucleocapsid assembly and prevents virus replication.
    Mateo M; Carbonnelle C; Martinez MJ; Reynard O; Page A; Volchkova VA; Volchkov VE
    J Infect Dis; 2011 Nov; 204 Suppl 3():S892-6. PubMed ID: 21987766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An analysis of features of pathogenesis in two animal models of Ebola virus infection.
    Ryabchikova EI; Kolesnikova LV; Luchko SV
    J Infect Dis; 1999 Feb; 179 Suppl 1():S199-202. PubMed ID: 9988185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV.
    Marthas ML; Miller CJ; Sutjipto S; Higgins J; Torten J; Lohman BL; Unger RE; Ramos RA; Kiyono H; McGhee JR
    J Med Primatol; 1992; 21(2-3):99-107. PubMed ID: 1433273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A single shot against Ebola and Marburg virus.
    Baize S
    Nat Med; 2005 Jul; 11(7):720-1. PubMed ID: 16015361
    [No Abstract]   [Full Text] [Related]  

  • 32. Successful topical respiratory tract immunization of primates against Ebola virus.
    Bukreyev A; Rollin PE; Tate MK; Yang L; Zaki SR; Shieh WJ; Murphy BR; Collins PL; Sanchez A
    J Virol; 2007 Jun; 81(12):6379-88. PubMed ID: 17428868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA vaccines for biodefense.
    Dupuy LC; Schmaljohn CS
    Expert Rev Vaccines; 2009 Dec; 8(12):1739-54. PubMed ID: 19943766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Developing methods of specific heterologic immunoglobulins preparation for urgent prevention of Ebola fever and study of their properties].
    Cherpunov AA; Kudoiarova-Zubavichene NM; Dedkova LM; Sergeev NN; Netesov SV
    Vestn Ross Akad Med Nauk; 1998; (4):24-9. PubMed ID: 9633237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental vaccine protects monkeys against Ebola virus.
    Gottlieb S
    Bull World Health Organ; 2001; 79(1):79. PubMed ID: 11217674
    [No Abstract]   [Full Text] [Related]  

  • 36. Virology. New vaccine and treatment excite Ebola researchers.
    Enserink M
    Science; 2003 Nov; 302(5648):1141-2. PubMed ID: 14615510
    [No Abstract]   [Full Text] [Related]  

  • 37. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins.
    Wilson JA; Bray M; Bakken R; Hart MK
    Virology; 2001 Aug; 286(2):384-90. PubMed ID: 11485406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins.
    Olinger GG; Bailey MA; Dye JM; Bakken R; Kuehne A; Kondig J; Wilson J; Hogan RJ; Hart MK
    J Virol; 2005 Nov; 79(22):14189-96. PubMed ID: 16254354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections.
    Geisbert TW; Hensley LE; Geisbert JB; Jahrling PB
    Virology; 2002 Feb; 293(1):15-9. PubMed ID: 11853394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Functional activity of peritoneal macrophages in experimental Ebola fever].
    Dadaeva AA; Sizikova LP; Chepurnov AA
    Vestn Ross Akad Med Nauk; 2004; (8):7-11. PubMed ID: 15455683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.